Background. BTK and PI3K inhibitors are increasingly used for treatment in patients with HM. OIs when these agents were used as first line therapy signaled an increased level of immunosuppression beyond what was expected from the mechanism of action of these drugs. The epidemiology of OIs in the setting of BTK and PI3K inhibitor use has not been characterized.
Methods. We retrospectively studied a cohort of patients with HM who received BTK (ibrutinib, acalabrutinib, spebrutinib) Results. 148 patients who received BTK or PI3K inhibitors as first or second line therapy were included in the study. Median age was 64.5 years, 32% were female, 95.9% had chronic lymphocytic leukemia (CLL), 4.1 % had Non-Hodgkin Lymphoma (NHL). Sixty-three percent received BTK inhibitors and 37% received PI3K inhibitors as first line therapy. Pneumocystis and HSV/VZV prophylaxis were used in 82.4% and 85.8% of patients, respectively. Twenty-seven OIs occurred in 24 patients. The most common OIs were pneumocystosis (7), aspergillosis (5) HSV (3), VZV (3), CMV (2), Cryptococcal meningitis (2), candidiasis (2) and other invasive mold infections (3). Seventy-one patients (48%) had infectious episodes not considered OIs. Median time to onset of OIs after start of therapy was 78 days (range, 6-323). Twelve OIs (8.1 %) occurred after first line therapy with BTK inhibitors, 11 OIs (7.4 %) occurred after first line PI3K inhibitors.
Conclusion. October 7, 2017: 12:30 PM Background. Pulmonary complications occur in 60% of hematopoietic stem cell transplant (HSCT) recipients with significant morbidity and mortality. Bronchoscopy with bronchoalveolar lavage (BAL) is an important diagnostic tool, but yield can be variable. The aim of this study was to investigate the utility of BAL in HSCT patients with new pulmonary infiltrates and determine factors associated with higher BAL yield.
Methods. Retrospective review of BAL results from January 2014 to July 2016. Included first bronchoscopy for HSCT patients over 18 years of age. Positive BAL determined by positive culture (bacterial, fungal, mycobacteria), viral PCR, elevated aspergillus galactomannan antigen (AGA), and cytology. Logistic regression analysis was performed.
Results. 54 HSCT recipients were included: 93% allogeneic, 34% neutropenic, 39% on prednisone, 59% on supplemental oxygen, 8% receiving mechanical ventilation (MV), 85% with multilobar infiltrates, 92% on antimicrobials (antibacterial 83%, antifungal 92%, antiviral 13%). 65% had positive BAL (23/54 bacterial, 16/54 elevated AGA, 6/54 fungal, 14/54 viral PCR, 1/54 mycobacteria). Median time to BAL from HSCT was 7.5 months. Not on levofloxacin prophylaxis (P = 0.004), not on MV (P = 0.037), or unrelated donor were associated with positive BAL results. Positive bacterial BAL culture was predictive of antibacterial escalation (P < 0.001). Elevated BAL AGA was associated with antifungal escalation and antibacterial de-escalation (P = 0.012). Antiviral initiation was more likely with positive BAL PCR (P = 0.002). Antifungal de-escalation (P = 0.047) and steroid initiation (P = 0.010) were more likely with negative BAL. 6 month mortality was 41%, and more likely with positive bacterial BAL culture (P = 0.046). Overall positive BAL was not predictive of mortality.
Conclusion. Bronchoscopy with BAL assisted in making critical management changes: elevated AGA with antifungal escalation and antibacterial de-escalation; and negative BAL with prednisone initiation and antifungal de-escalation. Unrelated donors, patients not on levofloxacin, or not on MV were more likely to have a positive BAL. Antimicrobial use likely reduced diagnostic yield for bacterial pathogens. Overall 6 month mortality was high, especially among those with bacterial infections. (FN) is a common complication to chemotherapy associated with a high burden of morbidity and mortality. Reliable prediction of individual risk based on pretreatment risk factors allows for stratification of preventive interventions. We aimed to develop such a risk stratification model to predict FN in the 30 days after initiation of chemotherapy.
Background. Febrile neutropenia
Methods. We included consecutive treatment-naïve patients with solid cancers and diffuse large B-cell lymphomas at Copenhagen University Hospital, 2010-2015. Data were obtained from the PERSIMUNE repository of electronic health records. FN was defined as neutrophils ≤0.5 × 10E9/L at the time of either a blood culture sample or death. Time from initiation of chemotherapy to FN was analyzed using FineGray models with death as a competing event. Risk factors investigated were: age, sex, body surface area, haemoglobin, albumin, neutrophil-to-lymphocyte ratio, Charlson Comorbidity Index (CCI) and chemotherapy drugs. Parameter estimates were scaled and summed to create the risk score. The scores were grouped into four: low, intermediate, high and very high risk.
Results. Among 8,585 patients, 467 experienced FN, incidence rate/30 person-days 0.05 (95% CI, 0.05-0.06). Age (1 point if > 65 years), albumin (1 point if < 39 g/L), CCI (1 point if > 2) and chemotherapy (range -5 to 6 points/drug) predicted FN. Median score at inclusion was 2 points (range -5 to 9). The cumulative incidence and the incidence rates and hazard ratios of FN are shown in Figure 1 and Table 1 , respectively.
Conclusion. We developed a risk score to predict FN the first month after initiation of chemotherapy. The score is easy to use and provides good differentiation of risk groups; the score needs independent validation before routine use.
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No reported disclosures. Results. Charts of 250 patients who received treatment with Ibrutinib were reviewed. Thirty-six excluded as they were lost to follow-up or received less than 30 days of Ibrutinib therapy. Among the 214 patients included, mean age was 65 (range 31-92) years and 161 (75%) were men. Eleven patients (5.1%) developed infection during the follow-up period: six cases of invasive aspergillosis (IA) (six pulmonary and one also involved the central nervous system (CNS)), twp cases of methicillin-resistant Staphylococcus aureus pneumonia, one case of CNS cryptococcal meningitis, one PJP Pneumonia, and one disseminated zoster (CNS meningoencephalitis). Of the 11 patients who developed infection, none was neutropenic at the time of infection and none received substantial corticosteroid courses. Apart from one patient who received combination therapy with ofatumumab, all patients who developed infection were receiving Ibrutinib monotherapy prior to the onset of infection.
Infections in Patients Receiving
Conclusion. Our data demonstrate that patients receiving Ibrutinib therapy for lymphoid malignancies are at risk for serious infections, including invasive fungal infections. The majority of infections in these patients developed in the absence of other risk factors for infection, suggesting that Ibrutinib may be independently associated with increased risk for certain infections.
